GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Phase 3
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT06868654
- Locations
- 🇨🇳
GSK Investigational Site, Zhengzhou, China
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Phase 3
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT06868667
- Locations
- 🇯🇵
GSK Investigational Site, Yokohama, Japan
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
Phase 3
Not yet recruiting
- Conditions
- Chickenpox
- Interventions
- Biological: Candidate varicella vaccineBiological: Marketed varicella vaccine
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 900
- Registration Number
- NCT06855160
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT06847867
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
Phase 3
Not yet recruiting
- Conditions
- Chickenpox
- Interventions
- Biological: Marketed varicella vaccineBiological: Investigational varicella vaccine
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 600
- Registration Number
- NCT06806137
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 8
- Registration Number
- NCT06790303
- Locations
- 🇫🇷
GSK Investigational Site, Bordeaux, France
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT06748053
- Locations
- 🇺🇸
GSK Investigational Site, American Fork, Utah, United States
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Phase 3
Recruiting
- Conditions
- Chickenpox
- Interventions
- Biological: Investigational varicella vaccine_Lot 1Biological: Investigational varicella vaccine_Lot 2Biological: Investigational varicella vaccine_Lot 3Biological: Marketed varicella vaccine_Lot 1Biological: Marketed varicella vaccine_Lot 2
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1840
- Registration Number
- NCT06740630
- Locations
- 🇺🇸
GSK Investigational Site, Layton, Utah, United States
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
Phase 1
Recruiting
- Conditions
- Kidney Disease
- Interventions
- Drug: Placebo matching GSK4771261
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT06734234
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 225
- Registration Number
- NCT06716606
- Locations
- 🇰🇷
GSK Investigational Site, Yongsan-Ku Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath